X0508 4 2024-11-25 0001034842 RIGEL PHARMACEUTICALS INC RIGL 0001820066 Santos David A RIGEL PHARMACEUTICALS, INC. 611 GATEWAY BLVD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 true EVP, Chief Commercial Officer false Employee Stock Option (right to buy) 18.7 2024-11-25 4 A 0 8000 0 A 2033-01-26 Common Stock 8000 8000 D The Reporting Person was granted a stock option with a performance-based condition with respect to 8,000 shares of the Issuer's common stock on January 26, 2023, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $18.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On November 25, 2024, it was determined that the performance metric had been met. The option was fully vested on November 25, 2024, the date the determination was made that the performance metric had been met. /s/ Raymond Furey (Attorney-in-Fact) 2024-11-26